trending Market Intelligence /marketintelligence/en/news-insights/trending/jV-nar_IfDYicjnOfiHybw2 content esgSubNav
In This List

US FDA accepts Sun Pharma application for eye treatment

Blog

Insight Weekly: M&A outlook; US community bank margins; green hydrogen players' EU expansion

Blog

Global M&A by the Numbers: Q2 2022

Blog

Insight Weekly: US bank M&A; low refinancing eases rates impact; Texas crypto mining booms

Blog

Infographic 2022 Top Tech Trends Shaping Corporations


US FDA accepts Sun Pharma application for eye treatment

Sun Pharmaceutical Industries Ltd. said the U.S. Food and Drug Administration accepted its new drug application for Seciera, a treatment for the dry eye disease.

The treatment, a clear aqueous solution, is now under review for approval by the regulator.

Once approved, Sun Pharma plans to commercialize Seciera in the U.S. through its subsidiary Sun Ophthalmics Inc.

Seciera, also known as OTX-101, previously met its main and secondary goals in a phase 3 trial in patients with the disease.